Results 181 to 190 of about 109,999 (323)

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

open access: yesBritish Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander   +5 more
wiley   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

open access: yesBritish Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Application of machine learning in forensic geochemistry using presalt oil samples from the Santos basin. [PDF]

open access: yesSci Rep
Silva GMA   +8 more
europepmc   +1 more source

Structure‐based discovery of thiamine uptake inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Thiamine (vitamin B1) is an essential coenzyme and catalyses various reactions in central metabolic pathways. Since mammals have lost the ability to synthesise thiamine de novo, this micronutrient has to be imported via the high affinity solute carriers SLC19A2 and A3 across the plasma membrane.
Florian Gabriel   +2 more
wiley   +1 more source

Therapeutic Potential of Tricyclic Pyridazinone-Based Molecules: An Overview. [PDF]

open access: yesInt J Mol Sci
Asproni B   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy